Radiant Biotherapeutics Appoints Deborah Geraghty, Ph.D., as President and Chief Executive Officer
Stefan Larson, Ph.D., incoming Chair of Radiant Biotherapeutics, commented: 'Dr. Geraghty brings a proven track record of building and transforming innovative biotechnology companies and we are delighted to welcome her to Radiant. Her deep industry expertise and strategic vision make her the ideal CEO to lead Radiant through this next phase of growth as we advance our lead clinical candidate, a 4-1BB agonist, toward clinical trials and expand our preclinical pipeline more broadly across oncology and autoimmunity.'
Dion Madsen, outgoing Chair and continuing Board Member of Radiant Biotherapeutics, noted: 'We are thrilled to welcome Stefan and Ingmar to our board of directors as we move towards the clinic with our lead program. The addition of Dr. Larson and Dr. Bruns brings relevant expertise necessary for us to successfully deliver our next-generation biologics to patients with cancer and autoimmune diseases. We appreciate Arthur Fratamico's leadership and foundational contributions to the Company during his four-year tenure as CEO.'
These appointments follow the company's successful $35 million Series A financing and build upon the recent progress by founding Chief Scientific Officer, Jo Hulme, Ph.D. Multabody™, Radiant's proprietary, best-in-class antibody platform, leverages remarkable avidity on intended targets while exploiting specificity to address multiple epitopes and different disease-modifying proteins. Antibodies developed using the Radiant platform are designed to deliver exceptional potency against both solid tumors and blood cancers, immunological targets, and infectious disease pathogens.
Deborah Geraghty, Ph.D., President and Chief Executive Officer of Radiant Biotherapeutics, added: 'What drew me to this role are the compelling preclinical data based on the strong scientific foundation of Radiant's unique biologic platform and the team that shepherded it this far. The opportunity to drive innovation for patients and realize the value of its application for devastating cancer and autoimmune diseases is energizing and I look forward to bringing these breakthrough therapies into the clinic.'
Deborah Geraghty, Ph.D., is an accomplished life sciences executive with over 20 years of experience having built a strong foundation of financial, operational and strategic expertise throughout her career leading innovative biopharmaceutical companies. She most recently served as President and CEO of Anokion SA, a Phase 2 clinical-stage Swiss biotech company focused on developing a new class of immune tolerance therapies for autoimmune disease. Prior to that, she was Senior Vice President of Corporate Strategy at Dimension Therapeutics, where she led Dimension's initial public offering and subsequent acquisition by Ultragenyx in 2017. Her earlier roles include co-founder and Vice President of Project and Portfolio Development at Cydan Development and leadership positions at Aileron Therapeutics as Head of Portfolio Advancement and Infinity Pharmaceuticals as Director of New Product Marketing. Dr. Geraghty holds a B.S. in Biology from Union College, an MBA from Boston College, and a Ph.D. in Molecular Biology from the University of Vermont.
Stefan Larson, Ph.D., is a Venture Partner at Sectoral Asset Management and serves on several biotech boards including Prilenia Therapeutics, Apnimed, and Stratus Therapeutics. He previously was an Entrepreneur-in-Residence and later Venture Partner at Versant Ventures, where he led the establishment of their Toronto-based Discovery Engine and served as founding CEO of Northern Biologics. Dr. Larson co-founded two medical device companies, Perimeter Medical Imaging and Tornado Spectral Systems, and began his career at McKinsey & Company. He holds a B.Sc. in Biology from McGill University, an M.Sc. in Molecular and Medical Genetics from University of Toronto, and a Ph.D. in Biophysics from Stanford University.
Ingmar Bruns, M.D., Ph.D., is a physician-scientist with two decades of hematology and oncology expertise who currently serves as Chief Medical Officer of Zentalis. He previously served as Chief Medical Officer of Trillium Therapeutics through its acquisition by Pfizer, then held senior clinical development roles at Pfizer, including head of the hematologic malignancies franchise. Earlier positions include Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals and clinical development leadership at Bayer Pharmaceuticals. Dr. Bruns served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf and Albert Einstein College of Medicine. He has authored over 50 publications in leading journals and holds an M.D. and Ph.D. from the University of Lubeck in Germany.
About Radiant Biotherapeutics
Radiant Biotherapeutics is biotechnology company committed to advancing and delivering transformative MULTi-specific, multi-Affinity antiBODY (Multabody™) therapeutics for patients with cancer and autoimmune diseases. Radiant's proprietary platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious biologics with superior potency than other antibody platforms, encompassing a new class of biologics positioned to address complex, heterogenous diseases such as cancer and autoimmune diseases. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages existing antibody CMC processes. With offices in Canada and the United States, Radiant has successfully delivered on numerous strategic partnerships that validate the platform's broad scientific and clinical utility. For more information, please visit radiantbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Terra Firma Energy Welcome UK Government Consultation on Hydrogen Blending into Great Britains Gas Transmission Network
LONDON--(BUSINESS WIRE)--At Terra Firma Energy, we welcome the UK Government's consultation into the blending of Hydrogen into Britain's Gas Transmission Network as a timely and positive step forward for both the UK's decarbonisation goals and the future of flexible power generation. All our projects are engineered to be hydrogen-ready from the outset, ensuring long-term operational flexibility and resilience in a rapidly evolving energy landscape. By anticipating changes in fuel supply and regulatory frameworks, we have future-proofed our generation assets to adapt quickly to low-carbon solutions like hydrogen blending. The ability to support hydrogen integration, even at early-stage blend levels, reinforces our commitment to sustainable innovation and positions our portfolio to contribute meaningfully to a net zero grid. Terra Firma Energy welcome UK Government Consultation on Hydrogen Blending into Great Britains Gas Transmission Network. Share The Department for Energy Security and Net Zero (DESNZ) has launched a new consultation exploring the potential for blending low-carbon hydrogen into Great Britain's gas transmission network. Following previous consultations on hydrogen blending into local distribution networks, the government is now seeking views on whether introducing hydrogen at the transmission level - the high-pressure National Transmission System (NTS) - could offer strategic and economic value. A Step Toward Net Zero Hydrogen is seen as a key player in the UK's push to reach net zero emissions by 2050. Blending low-carbon hydrogen with natural gas could offer a transitional path, supporting early-stage hydrogen production while reducing the carbon intensity of the existing gas network. DESNZ is currently evaluating whether to enable blending of up to 2% hydrogen by volume into the NTS. This small percentage could act as an 'off-taker of last resort' for hydrogen producers, providing a backup market when dedicated customers are not available. Balancing Innovation with Risk The consultation outlines both the potential benefits and challenges. While hydrogen blending could support the growth of the hydrogen economy and help manage electricity system constraints, it also raises concerns for industrial users connected to the transmission system. Many of these users rely on stable, high-quality gas supplies, and even a 2% hydrogen blend could affect equipment performance, increase costs, or require infrastructure upgrades. Terra Firma Energy have been proactive in ensuring all our projects have been built utilising hydrogen ready generation sets that can accommodate a 20% blend of hydrogen into the network. Studies cited in the consultation show that most transmission-connected users could technically handle a 2% blend with minimal changes, though feasibility studies and equipment modifications may still be necessary. At higher blends (5% or 20%), the risks and costs escalate significantly. Cross-Border Considerations The UK's ability to blend hydrogen is also influenced by developments in the EU. Under the EU Hydrogen and Decarbonised Gas Market Package, Member States can blend up to 2% hydrogen by volume, but are not required to do so. This creates potential interoperability issues with the UK's gas inter-connectors to Ireland, Belgium, and the Netherlands - especially if hydrogen blends exceed that threshold.
Yahoo
21 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Time Business News
2 days ago
- Time Business News
Ford: A Timeless Journey of Innovation, Strength, and Legacy
Few automotive brands carry the weight of history and innovation quite like Ford. It's more than just a company—it's a global icon, a symbol of progress, and a trusted name woven into the fabric of modern society. From the roaring engines of classic muscle cars to the silent hum of next-gen electric vehicles, Ford represents a legacy of freedom, reliability, and bold vision. For over a century, Ford has stood as a pioneer of both industry and imagination. Whether you're cruising down a coastal highway or hauling heavy loads across rugged terrain, Ford drives dreams forward—generation after generation. In 1903, a visionary named Henry Ford changed the course of transportation forever. He didn't just build cars—he built a movement. Ford believed that every individual, not just the wealthy, deserved access to mobility. This dream gave birth to the Model T, the car that put the world on wheels. What truly set Ford apart was the introduction of the moving assembly line in 1913. This groundbreaking innovation reduced manufacturing time, lowered costs, and allowed Ford to pay workers fair wages. It wasn't just a business decision—it was a social revolution. In many ways, Ford helped shape the modern middle class. What began in a modest Detroit workshop has grown into a global powerhouse. Today, Ford operates in more than 100 countries, with production plants, design studios, and dealerships around the globe. Each region sees its piece of the Ford experience—from compact cars in Asia to heavy-duty trucks in the Americas. But despite its global presence, Ford maintains its core identity: durability, innovation, and customer trust. That's why you'll see a Ford at a dusty construction site in Texas, a rally course in Kenya, or a city street in London—proving that Ford is truly built for every road, every driver. Ford's legacy is one of constant reinvention. While honoring its heritage, Ford has always had one foot in the future. Recent years have seen an incredible wave of technological innovation: Ford Co-Pilot360™ : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. SYNC Infotainment System : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. FordPass™ App: A smartphone gateway to remote start, lock/unlock, locate your vehicle, schedule service appointments, and more. Innovation isn't a trend for Ford—it's part of its DNA. The automotive world is shifting, and Ford is leading the charge—literally. With a multi-billion-dollar investment in electric vehicle (EV) infrastructure, Ford is committed to a cleaner, brighter, and more efficient future. Mustang Mach-E : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. F-150 Lightning : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. E-Transit Van: Designed for commercial use, this EV delivers zero-emissions transport without sacrificing payload or functionality. Ford is more than ready for tomorrow—it's building it today. If there's one phrase that perfectly defines Ford's spirit, it's 'Built Ford Tough.' Ford's lineup of trucks—especially the iconic F-Series—has been trusted by hard-working individuals for generations. The Ford F-150, in particular, is the best-selling vehicle in the United States for over 40 years. It's not just popular; it's legendary. With exceptional towing capacity, military-grade aluminum alloy construction, hybrid powertrain options, and rugged styling, it's built for those who demand power, performance, and perseverance. Ford understands that authentic leadership means protecting the world we share. That's why sustainability is a core focus: Committed to carbon neutrality by 2050 Manufacturing plants powered by renewable energy Use of recycled and sustainable materials in new vehicle production in new vehicle production Innovation in battery technology and EV charging infrastructure Ford isn't just adapting to environmental responsibility—it's setting the standard. For millions, owning a Ford is more than transportation—it's a relationship. It's the car that taught your teenager to drive, the truck that hauled your first home, the Mustang that turned heads, or the van that took your family on summer road trips. Ford vehicles are in the photos of your memories, in the heart of your journeys, and in the conversations passed down from one generation to the next. This emotional bond is what makes Ford timeless. From Steve McQueen's 1968 Mustang in Bullitt to Will Smith's futuristic Ford GT in I, Robot , Ford has become a pop culture icon. Songs, movies, video games—you'll find Ford roaring across them all. That's because Ford is more than a car—it's a character, a symbol, and a source of inspiration. With over a century of legacy, innovation, and trust, Ford remains a brand like no other. It's a company that stays true to its roots while courageously reimagining the future. Whether you're a die-hard Mustang enthusiast, a rugged F-150 driver, or a first-time EV owner, Ford welcomes you with open arms—and an open road. Because with Ford, the drive never ends. TIME BUSINESS NEWS
